signumia
Data is being collected. The dashboard will appear when it is available.
SYMBOL
Data is being collected. The dashboard will appear when it is available.
SXTP

Close price

$1.69

Latest price

$1.69

Change vs close

+0.00%

Current price: $1.69

Market cap

4.49M

Pre-market and after-hours data may be partial or delayed depending on the source and licensing.

60 Degrees Pharmaceuticals, Inc.

SXTP

NASDAQ-CM · Health Care · Biotechnology: Pharmaceutical Preparations

Company Profile

60 Degrees Pharmaceuticals, Inc., founded in 2010, specializes in developing and commercializing new medicines for the treatment and prevention of vector-borne disease. The Company achieved U.S. Food and Drug Administration approval of its lead product, ARAKODA® ( tafenoquine ), for malaria prevention in 2018. ARAKODA is commercially available in the U.S. and Australia. 60 Degrees Pharmaceuticals, Inc. also collaborates with prominent research and academic organizations in the U.S. and Australia. 60 Degrees Pharmaceuticals, Inc. is headquartered in Washington, D.C., with a subsidiary in Australia. Learn more at www.60degreespharma.com.

Website

https://www.60degreespharma.com

Country

DC

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

CIK

0001946563

Candlestick Chart

1D · Data source: loading

Loading candle data

Quarterly Performance Snapshot

Actual revenue and net income based on quarterly filings

Q1 Mar 2026

Quarterly Snapshot

Q1 Mar 2026

Mix

4.66M

Market cap

96.52%

4.49M

Quarterly revenue

3.48%

162K

Market cap / revenue

27.74x

Revenue

162K

Previous quarter

-48.73%

Net income

-2.09M

Previous quarter

-45.17%

Revenue and Net Income Trend

RevenueNet income

Quarterly Performance

12 quarters

Financial Statements

SEC Filings

12 filings shown

Open the original SEC filings to view the full document.

FormFiling DateReport DateAccessionLink
4Jun 15, 2026Jun 12, 20260001213900-26-068853Document
PRE 14AJun 8, 2026Jun 8, 20260001213900-26-066363Document
8-KJun 3, 2026Jun 3, 20260001213900-26-064796Document
3May 19, 2026May 13, 20260001213900-26-059167Document
8-KMay 18, 2026May 13, 20260001213900-26-058495Document
SCHEDULE 13G/AMay 15, 2026No data0001213900-26-057698Document
SCHEDULE 13G/AMay 15, 2026No data0001649553-26-000060Document
10-QMay 15, 2026Mar 31, 20260001554855-26-001058Document
SCHEDULE 13G/AMay 13, 2026No data0001213900-26-055849Document
10-KMar 30, 2026Dec 31, 20250001554855-26-000467Document
8-KMar 20, 2026Mar 20, 20260001213900-26-032352Document
424B5Mar 13, 2026No data0001213900-26-027763Document

Latest News

12 articles
RTTNewsMay 27, 2026, 12:00 AMnasdaq

60 Degrees Announces Early Enrollment In Study For Tafenoquine In Treating Babesiosis

(RTTNews) - 60 Degrees Pharmaceuticals (SXTP), a pharmaceutical company, on Wednesday announced the early enrollment of the first patient in a clinical study evaluating Taafenoquine in treating babesiosis.

Open article
ZacksMay 13, 2026, 12:00 AMnasdaq

Aquestive Therapeutics (AQST) Reports Q1 Loss, Beats Revenue Estimates

Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of +50.00% and +33.22%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Open article
ZacksMay 11, 2026, 12:00 AMnasdaq

Heron Therapeutics (HRTX) Reports Q1 Loss, Lags Revenue Estimates

Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -33.33% and -3.91%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Open article
ZacksApr 3, 2026, 12:00 AMnasdaq

60 Degrees Pharmaceuticals Inc. (SXTP) Upgraded to Buy: Here's What You Should Know

60 Degrees Pharmaceuticals Inc. (SXTP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Open article
RTTNewsMar 13, 2026, 12:00 AMnasdaq

Weekly Buzz: BMY Wins FDA Nod; EU Okays JNJ's AKEEGA; IPSEY Withdraws Tazverik, DAWN Acquired

(RTTNews) - This week's biotech landscape witnessed key FDA approvals, EU approvals, IND clearances, acquisitions, and clinical trial data readouts across key therapeutic areas such as Chronic Inflammatory Demyelinating Polyneuropathy, Atopic Dermatitis, Ornithine Transcarbamylas

Open article
RTTNewsMar 12, 2026, 12:00 AMnasdaq

60 Degree Announces All Patients Cured For Babesiosis With Tafenoquine

(RTTNews) - 60 Degree Pharmaceuticals, Inc. (SXTP) announced that all three patients enrolled in its expanded use clinical trial of Tafenoquine were cured of relapsing babesiosis, underscoring the drug's potential as a breakthrough therapy for this serious tick-borne illness.

Open article
FintelFeb 4, 2026, 12:00 AMnasdaq

60 Degrees Pharmaceuticals (SXTP) Price Target Increased by 300.00% to 17.95

The average one-year price target for 60 Degrees Pharmaceuticals (NasdaqCM:SXTP) has been revised to $17.95 / share. This is an increase of 300.00% from the prior estimate of $4.49 dated January 11, 2026. The price target is an average of many targets provided

Open article
RTTNewsJan 28, 2026, 12:00 AMnasdaq

SXTP Climbs On Licence Agreement With Florida State University For Castanospermine Extraction

(RTTNews) - 60 Degrees Pharmaceuticals, Inc. (SXTP; SXTPW) a firm focused on developing new medicines for vector-borne disease, on Thursday announced that it has exercised an exclusive license with Florida State University to use large-scale purification techniques to extract cas

Open article
RTTNewsJan 22, 2026, 12:00 AMnasdaq

60 Degrees Pharma Announces Partnership With Runway Health To Expand ARAKODA Access; Stock Surges

(RTTNews) - 60 Degrees Pharmaceuticals, Inc. (SXTP) has entered a new partnership with Runway Health to provide international travelers with streamlined, pre-departure access to ARAKODA, the only FDA-approved, once-weekly prescription option for malaria prevention in the United S

Open article
RTTNewsJan 16, 2026, 12:00 AMnasdaq

60 Degree Pharma To Implement 1-for-4 Reverse Stock Split To Regain Nasdaq Compliance

(RTTNews) - 60 Degree Pharmaceuticals, Inc. (SXTP) is preparing to consolidate its shares in a one-for-four (1:4) reverse stock split, a step aimed at regaining compliance with Nasdaq's minimum bid price requirement and stabilizing its capital-market position.

Open article
ZacksDec 23, 2025, 12:00 AMnasdaq

Here's Why 60 Degrees Pharmaceuticals Inc. (SXTP) Looks Ripe for Bottom Fishing

60 Degrees Pharmaceuticals Inc. (SXTP) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Open article
FintelNov 28, 2025, 12:00 AMnasdaq

Ascendiant Capital Maintains 60 Degrees Pharmaceuticals (SXTP) Buy Recommendation

Fintel reports that on November 28, 2025, Ascendiant Capital maintained coverage of 60 Degrees Pharmaceuticals (NasdaqCM:SXTP) with a Buy recommendation. Analyst Price Forecast Suggests 531.43% Upside

Open article